image description

Tag: lupus therapeutics

Dr. Daniel Wallace Appointed to Lupus Therapeutics Board

New York, NY, July 18, 2019 — Renowned Dr. Daniel Wallace joined the Lupus Research Alliance (LRA) affiliate Lupus Therapeutics  Board of Directors.   This governing body, which includes lupus patients, family members and scientists,  provides strategic insight and financial oversight to help Lupus Therapeutics achieve its mission –accelerate new ways to diagnose and treat lupus. Read More

Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb to Test Potential Treatment for Lupus

New York, NY– June 27, 2019.  The Lupus Research Alliance (LRA) and clinical research affiliate, Lupus Therapeutics, broadened a collaboration with Bristol-Myers Squibb (BMS) to study the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN) – kidney damage affecting about 50 percent of people with lupus. This expands the existing collaboration in systemic lupus erythematosus (SLE). […] Read More

Join Us at Lupus Research and Advocacy Conference

Find Out How Lupus Research Can Transform Lives at a Free Conference and Cocktail Reception  Learn about the newest advances in lupus research and how to advocate for more research funding from the federal government, to support future discoveries. Wednesday, July 17, 2019 5:45 PM Reception 7:00 PM Panel Discussion iHeartMedia 125 W 55th Street […] Read More

LRA Researchers Reveal New Drug Targets at Leading Immunology Conference

May 22, 2019 Data presented by several Lupus Research Alliance-funded scientists at the recent American Association of Immunologists Annual Meeting suggests many  avenues for new lupus treatments. Some scientists presented data posing new targets for drug development, while others have discovered cells that suppress the immune response and could be harnessed as treatments. Reining in […] Read More

Celebrate Clinical Trials Day May 20!

May 20, 2019 It’s Clinical Trials Day when the Lupus Research Alliance recognizes all the people we support who advance clinical research – scientists who identify and develop potential ways to diagnose, monitor and treat lupus,  researchers who design and conduct the studies to test these methods, and the volunteers who take part in the […] Read More

A Promising New Therapy

April, 2019 As our name implies, the Lupus Research Alliance aims to forge partnerships and bring other players  to the table to better understand and treat lupus — and our latest venture holds the promise of a new therapy. We — and our affiliate, Lupus Therapeutics — are about to collaborate with Takeda Pharmaceutical Company […] Read More

Taking Scientific Discovery: From Lab Bench to You

April, 2019 Making new and efficacious lupus therapies available to patients has long been a major focus of the Lupus Research Alliance, and today we’ve taken an important step toward that aim. Based on a breakthrough discovery made by Betty Diamond, MD of Feinstein Institutes for Medical Research, Meggan Mackay, MD, MS, also at Feinstein, will […] Read More

Lupus Therapeutics to Test Potential Treatment for Lupus in Takeda Collaboration

New York, NY– March 1.  The Lupus Research Alliance and clinical affiliate, Lupus Therapeutics will partner with Takeda Pharmaceutical Company Limited to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a Phase 1 trial (NCT03724916).  TAK-079 is a fully human monoclonal antibody, meaning that it is produced in the laboratory using human […] Read More

Stelara® and Olumiant® Considered Promising by Lupus Expert

February 19, 2019 In Healio Rheumatology, Dr. Gregg Silverman, professor of medicine and pathology at NYU School of Medicine, provided an overview of potential lupus therapies in development.  He highlighted ustekinumab (brand name Stelara®) and baricitinib (brand name Olumiant®) as two drugs that look particularly promising. “The phase 2 extra-renal trial of baricitinib looks good; […] Read More

Lupus Therapeutics Launches Peer Training Program to Help Patients Benefit from Clinical Trials

NEW YORK, NY. February 1, 2019. Lupus Research Alliance clinical affiliate Lupus Therapeutics launched the Patient Advocates for Lupus Studies (PALS) program with a pilot study to determine its effectiveness in increasing awareness of and participation in lupus clinical trials, particularly among diverse populations.  PALS was formed to address the pressing issue of underrepresentation in clinical studies […] Read More